Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>Claire Wainwright, Michael Boyle, À. Munck et al.|New England Journal of Medicine|2015Cited by 1.6k
<i>Pseudomonas aeruginosa</i>infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approachesHelena Lund‐Palau, Jane C. Davies, A R Turnbull et al.|Expert Review of Respiratory Medicine|2016Cited by 170
Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosisWynne D. Smith, Jane C. Davies, Emmanuelle Bardin et al.|FEMS Microbiology Letters|2017Cited by 107
The<i>Staphylococcus aureus</i>Network Adaptive Platform Trial Protocol: New Tools for an Old FoeSteven Y. C. Tong, Adrian Dunlop, Jocelyn Mora et al.|Clinical Infectious Diseases|2022Cited by 98
Metabolic Phenotyping and Strain Characterisation of Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients Using Rapid Evaporative Ionisation Mass SpectrometryEmmanuelle Bardin, Zoltán Takáts, Simon J. S. Cameron et al.|Scientific Reports|2018Cited by 33